| abstract |
The present invention generally relates to nuclear transport modulators, such as CRM1 inhibitors, and more particularly to compounds represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also encompasses methods of synthesizing a compound of formula (I) or a pharmaceutically acceptable salt or composition thereof and their use in the treatment, control and / or prevention of physiological conditions, such as those associated with CRM1 activity: In the above formulas, the significance and alternative meanings for the variables are as defined and described herein. |